Bisfluoroalkyl Benzodiazepinone Combination Patent Application by Ayala Pharma

The EPO published patent application EP3790552A1 for Ayala Pharmaceuticals Inc., covering bisfluoroalkyl-1,4-benzodiazepinone compounds and their combination compositions for therapeutic use. The application discloses compounds classified under multiple A61K subclasses including benzodiazepinones (A61K 31/5513), phosphorous-containing compounds (A61K 31/661), and combinations with agents such as A61K 31/436 and A61K 33/243. The therapeutic classifications A61P 35/00 (antineoplastic agents) and A61P 35/02 (leukemia) indicate the primary clinical focus. The publication designates all 39 European Patent Convention contracting states, establishing a filing date of April 15, 2026 for priority purposes.

For parties monitoring the pharmaceutical patent landscape, this publication signals Ayala Pharma's development activities in oncology therapeutics involving benzodiazepinone scaffolds. Competitors developing similar compounds should review the published claims for potential freedom-to-operate issues. The application is now publicly available for third-party review and potential opposition once the grant stage is reached.